2.02
-0.11(-5.16%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.19 |
| Day High | 2.2 |
| Day Low | 2.01 |
| 52-Week High | 3.25 |
| 52-Week Low | 0.61 |
| Volume | 1.37M |
| Average Volume | 2.26M |
| Market Cap | 337.52M |
| PE | -1.37 |
| EPS | -1.47 |
| Moving Average 50 Days | 2.18 |
| Moving Average 200 Days | 1.56 |
| Change | -0.11 |
If you invested $1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth $124.31 as of January 19, 2026 at a share price of $2.02. Whereas If you bought $1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 2 years ago, it would be worth $141.75 as of January 19, 2026 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
GlobeNewswire Inc.
Jan 05, 2026 11:35 AM GMT
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
GlobeNewswire Inc.
Jan 05, 2026 11:30 AM GMT
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demo
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbi